Is CNMD a good stock to buy? We came across a bullish thesis on CONMED Corporation on Valueinvestorsclub.com by anton613. In this article, we will summarize the bulls’ thesis on CNMD. CONMED Corporation’s share was trading at $36.79 as of April 28th. CNMD’s trailing P/E was 25.08 according to Yahoo Finance.
Conmed Corporation (CNMD) is a medical technology company focused on orthopedic and general surgery products, and its shares appear significantly undervalued following a period of operational challenges that have masked underlying stability and recovery. The business generates 58% of revenue from general surgery and benefits from a highly recurring model, with single-use products accounting for 86% of total sales and 77% of orthopedic revenue, supporting consistent cash flows.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Its orthopedic segment includes a broad portfolio of implants and surgical tools, while general surgery is anchored by differentiated offerings such as the AirSeal system, alongside energy devices and endomechanical products. Despite headwinds from supply chain disruptions, tariffs, and manufacturing inefficiencies, Conmed has demonstrated resilience, delivering 5.2% constant currency sales growth in 2025 and double-digit orthopedic growth in the fourth quarter.
Management has made tangible progress in resolving supply constraints, with backorders at three-year lows, while strategic actions such as exiting the gastroenterology business are expected to improve gross margins. Growth drivers including AirSeal, Buffalo Filter, and BioBrace continue to expand adoption, reinforcing long-term positioning.
For 2026, the company guides to mid-single-digit revenue growth and underlying EPS expansion when adjusting for divestiture impacts, alongside margin improvement despite tariff pressures. With a new $150 million share repurchase program and stable leverage, Conmed is positioned for recovery. Trading at roughly 8x earnings versus peers near 20x, a re-rating to even 15x implies substantial upside, with potential exceeding 50% as execution improves or strategic interest emerges.
Previously, we covered a bullish thesis on Stryker Corporation (SYK) by The Antifragile Investor in January 2025, which highlighted the company’s innovation-led growth through robotic surgery, strong MedTech portfolio, and consistent expansion across segments. SYK’s stock price has depreciated by approximately 10.95% since our coverage. anton613 shares a similar view but emphasizes on Conmed’s undervaluation and turnaround-driven upside potential.
CONMED Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held CNMD at the end of the fourth quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of CNMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CNMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
